Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Company Overview

Sunshine Biopharma, Inc. is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines.

The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.

Key Stats

• Today's Range: $1.03 to $1.09
• 50-Day Range: $0.96 to $1.23
• 52-Week Range: $0.95 to $2.43
• Volume: 25,727 shs
• Average Volume: 37,926 shs
• Market Capitalization: $5.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Sunshine Biopharma Stock Analysis - MarketRank™

Sunshine Biopharma scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Sunshine Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Sunshine Biopharma has a consensus price target of $7.00, representing about 560.4% upside from its current price of $1.06.

Amount of Analyst Coverage

Sunshine Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sunshine Biopharma is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sunshine Biopharma is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sunshine Biopharma has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.74% of the float of Sunshine Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sunshine Biopharma has a short interest ratio ("days to cover") of 3.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sunshine Biopharma has recently decreased by 4.03%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sunshine Biopharma does not currently pay a dividend.

Dividend Growth

Sunshine Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sunshine Biopharma this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.04% of the stock of Sunshine Biopharma is held by insiders.

Percentage Held by Institutions

41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/03/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SBFM
• CIK: 1402328
• Web: www.sunshinebiopharma.com
• Phone: (514) 426-6161
• Fax: N/A
• Employees: 3
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Sunshine Biopharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +560.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.97 million
• Net Margins: -17.86%
• Pretax Margin: -16.40%
• Return on Equity: -27.14%
• Return on Assets: -21.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.17
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: $36.31 million
• Price / Sales: 0.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.69 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 4,910,000
• Free Float: 4,904,000
• Market Cap: $5.20 million
• Optionable: Not Optionable
• Beta: 1.37